No Data
No Data
Karen Zaderej Spends US$100k Buying EyePoint Pharmaceuticals Shares
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments
Some Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Estimates
Express News | JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29
EyePoint Pharmaceuticals Analyst Ratings